Perceptive Advisors GPCR Position
Exited15-Fund ConvergencePerceptive Advisors exited their position in Structure Therapeutics Inc. (GPCR) in Q4 2024, after holding the stock for 3 quarters.
The position was first reported in Q2 2024 and has been tracked across 3 quarterly 13F filings.
GPCR is a convergence signal: 15 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for Aleniglipron or Placebo in 106 days (Jul 31, 2026), making the timing of Perceptive's position particularly relevant.
About Structure Therapeutics Inc.
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.
Full company profile →Short Interest
9.9%
6.5 days to cover
Perceptive Advisors GPCR Position History
Frequently Asked Questions
Does Perceptive Advisors own GPCR?
No. Perceptive Advisors exited their position in Structure Therapeutics Inc. (GPCR) in Q4 2024. They previously held the stock for 3 quarters.
How many hedge funds own GPCR?
15 specialist biotech hedge funds currently hold GPCR, including Avoro Capital Advisors, Deep Track Capital, BVF Partners and 12 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Perceptive Advisors first buy GPCR?
Perceptive Advisors's position in GPCR was first reported in Q2 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Perceptive Advisors's GPCR position increasing or decreasing?
Perceptive Advisors completely exited their GPCR position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
GPCRCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Perceptive AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →